Zydus Lifesciences obtains a sign of Health Canada for Liothyronine Tablets

Liothyronine, a synthetic form of T3 thyroid hormone (triiodothyronin), is mainly used to treat hypothyroidism. The tablets will be made in the installation of Zydus Ahmedabad Sez.

The product made annual sales of $ 10.9 million Canadian dollars in Canada, according to IQVIA MAT data for June 2025.

Zydus, including its subsidiaries and affiliates, said that approval will allow it to market the drug in Canada, expanding its footprint on the North American generic market. Zydus Lifesciences Limited is a diversified Indian Pharmaceutical Company engaged in the research, development, manufacturing and marketing of a wide range of health products. Its portfolio covers brand formulations, generics, biosimilars, active pharmaceutical ingredients (API), vaccines and over -the -counter products.

Based in Ahmedabad, the company operates worldwide, with a strong presence in North America, Europe and emerging markets.

Read also: Zydus Life Q1 Results: Fy26 Guide maintained, but actions fall under moderate gains

In a separate announcement, Zydus said it had obtained the final approval of the US Food and Drug Administration (USFDA) for the DEFLAZACORT oral suspension, 22.75 mg / ml, a generic version of the Emflaza oral suspension.

Steroid medication is used to treat Duchenne muscular dystrophy (DMD) in patients aged five and over, helping to reduce inflammation and modulate a hyperactive immune response. Zydus will make the product in its doppel installation in Italy. With this latest approval, the group’s cumulative approvals of the group reach 424, out of 487 new abbreviated medication requests (Andas) since it entered the submission in 2003-04.